Calliditas Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Calliditas Therapeutics' es Renee Aguiar-Lucander , nombrado en May 2017, tiene una permanencia de 7.08 años. compensación anual total es SEK18.37M, compuesta por 36.6% salario y 63.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.2% de las acciones de la empresa, por valor de SEK133.87M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 5.1 años, respectivamente.
Información clave
Renee Aguiar-Lucander
Chief Executive Officer (CEO)
kr18.4m
Compensación total
| Porcentaje del salario del CEO | 36.6% |
| Permanencia del CEO | 7.1yrs |
| Participación del CEO | 1.2% |
| Permanencia media de la dirección | 3.3yrs |
| Promedio de permanencia en la Junta Directiva | 5.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results
Feb 24
Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Jan 12Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost
Dec 22Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?
Sep 22What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today
Aug 19Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%
May 26Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?
Feb 24Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Nov 25Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%
Aug 24Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?
Aug 03Is Calliditas Therapeutics (STO:CALTX) A Risky Investment?
Apr 24Need To Know: The Consensus Just Cut Its Calliditas Therapeutics AB (publ) (STO:CALTX) Estimates For 2022
Mar 19Analysts' Revenue Estimates For Calliditas Therapeutics AB (publ) (STO:CALTX) Are Surging Higher
Feb 28Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 27Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -kr525m |
| Dec 31 2023 | kr18m | kr7m | -kr466m |
| Sep 30 2023 | n/a | n/a | -kr451m |
| Jun 30 2023 | n/a | n/a | -kr292m |
| Mar 31 2023 | n/a | n/a | -kr393m |
| Dec 31 2022 | kr13m | kr6m | -kr412m |
| Sep 30 2022 | n/a | n/a | -kr628m |
| Jun 30 2022 | n/a | n/a | -kr608m |
| Mar 31 2022 | n/a | n/a | -kr576m |
| Dec 31 2021 | kr11m | kr5m | -kr500m |
| Sep 30 2021 | n/a | n/a | -kr452m |
| Jun 30 2021 | n/a | n/a | -kr600m |
| Mar 31 2021 | n/a | n/a | -kr501m |
| Dec 31 2020 | kr7m | kr3m | -kr433m |
| Sep 30 2020 | n/a | n/a | -kr286m |
| Jun 30 2020 | n/a | n/a | -kr198m |
| Mar 31 2020 | n/a | n/a | -kr54m |
| Dec 31 2019 | kr4m | kr3m | -kr33m |
| Sep 30 2019 | n/a | n/a | -kr54m |
| Jun 30 2019 | n/a | n/a | -kr35m |
| Mar 31 2019 | n/a | n/a | -kr136m |
| Dec 31 2018 | kr4m | kr2m | -kr132m |
Compensación vs. Mercado: La compensación total de Renee($USD1.20M) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD584.33K).
Compensación vs. Ingresos: La compensación de Renee ha aumentado mientras la empresa no es rentable.
CEO
Renee Aguiar-Lucander (62 yo)
7.1yrs
Permanencia
kr18,367,000
Compensación
Ms. Renee Aguiar-Lucander serves as Director at Genkyotex SA since November 2020. Ms. Aguiar-Lucander has been Chief Executive Officer of Calliditas Therapeutics AB (publ) since May 2017. Prior to joining...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chief Executive Officer | 7.1yrs | kr18.37m | 1.2% SEK 133.9m | |
| Chief Financial Officer | 6.8yrs | sin datos | 0.080% SEK 8.9m | |
| Head of Technical Operations | 1.4yrs | sin datos | sin datos | |
| Head of IR & Sustainability | 1.4yrs | sin datos | sin datos | |
| Group General Counsel | 1.4yrs | sin datos | sin datos | |
| Head of Human Resources | 4.4yrs | sin datos | sin datos | |
| Head of Clinical Development & VP of Project Management | 7.4yrs | sin datos | sin datos | |
| Chief Medical Officer | 3.9yrs | sin datos | sin datos | |
| Head of US Marketing | 3.3yrs | sin datos | sin datos | |
| Head of US Sales | 3.3yrs | sin datos | sin datos | |
| President of North America | less than a year | sin datos | sin datos | |
| Vice President of Market Access | no data | sin datos | sin datos |
3.3yrs
Permanencia media
49yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CALTX se considera experimentado (3.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Independent Non-Executive Director | 5.1yrs | kr795.00k | 0.031% SEK 3.5m | |
| Independent Chairman | 5.1yrs | kr1.74m | 0.086% SEK 9.6m | |
| Independent Non-Executive Director | 2.1yrs | kr762.00k | 0.019% SEK 2.1m | |
| Independent Director | 2.1yrs | kr587.00k | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Non-Executive Director | 9.8yrs | kr731.00k | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
5.1yrs
Permanencia media
65yo
Promedio de edad
Junta con experiencia: La junta directiva de CALTX se considera experimentada (4.9 años de antigüedad promedio).